CYT387

CYT387 is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 1/2.

Price Stock Quantity  
In DMSO USD 220 In stock
USD 170 In stock
USD 470 In stock
USD 1270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

CYT387 Chemical Structure

CYT387 Chemical Structure
Molecular Weight: 414.46

Validation & Quality Control

Customer Reviews(1)

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare JAK Inhibitors
    Compare JAK Inhibitors
  • Research Area

Product Description

Biological Activity

Description CYT387 is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 1/2.
Targets JAK1 JAK2 JAK3
IC50 11 nM 18 nM 155 nM [1]
In vitro CYT387 inhibits the proliferation of parental Ba/F3 cells (Ba/F3-wt) stimulated by IL-3 with IC50 of 1400 nM. Furthermore, CYT387 also causes the inhibition of cell proliferation in cell lines constitutively activated by JAK2 or MPL signaling, including Ba/F3-MPLW515L cells, CHRF-288-11 cells and Ba/F3-TEL-JAK2 cells with IC50 of 200 nM, 1 nM and 700 nM, respectively. In addition, CYT387 has been shown to inhibit erythroid colony growth in vitro from JAK2V617F-positive PV patients with similar potency with IC50 of 2μ-4 μM. [1] A recent study shows that CYT387 inhibits PI3K/AKT and Ras/MAPK signaling induced by IL-6 and IGF-1. Moreover, CYT387 induces apoptosis as a single agent and synergizes with the conventional anti-MM therapies bortezomib and melphalan in primary multiple myeloma (MM) cells. [2]
In vivo In a murine MPN model, CYT387 normalizes white cell counts, hematocrit, spleen size, and restores physiologic levels of inflammatory cytokines. [3]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Cell-free kinase activity assays Glutathione-S-transferase (GST)-tagged JAK kinase domains expressed in insect cells are purified before use in a peptide substrate phosphorylation assay. Assays are carried out in 384-well optiplates using an Alphascreen Protein Tyrosine Kinase P100 detection kit and a PerkinElmer Fusion Alpha instrument.

Cell Assay: [1]

Cell lines Ba/F3, Ba/F3-JAK2V617F and Ba/F3-MPLW515L cells
Concentrations 0 to 10 μM
Incubation Time 72 hours
Method Ba/F3 cells expressing JAK2V617F (Ba/F3-JAK2V617F) and MPLW515L (Ba/F3-MPLW515L) mutants, as well as CHRF-288-11 (JAK2T875N) and CMK (JAK3A572V) cells are used. The TEL/JAK2 and TEL/JAK3 fusions are generated and introduced into Ba/F3 murine cells. The TEL/JAK2- or TEL/JAK3-transfected cells are cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS). Ba/F3 wild-type cells are cultured in RPMI containing 10% FCS supplemented with 5 ng/mL murine IL-3. Proliferation is measured using the Alamar Blue assay after incubating for 72 hours at 37 °C with 5% CO2

Animal Study: [3]

Animal Models Balb/c mice are transplanted with bone marrow transduced with a JAK2V617F retrovirus.
Dosages ≤50 mg/kg
Administration Administered via p.o.
Solubility 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL
1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00935987 Completed Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis Gilead Sciences 2009-11 Phase 1|Phase 2
NCT01236638 Active, not recruiting Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis Gilead Sciences 2010-11 Phase 2
NCT01423058 Active, not recruiting Primary Myelofibrosis|Post-Polycythemia Vera|Post-Essential Thrombocythemia Myelofibrosis Gilead Sciences 2011-08 Phase 1|Phase 2

Chemical Information

Download CYT387 SDF
Molecular Weight (MW) 414.46
Formula

C23H22N6O2

CAS No. 1056634-68-4
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms CYT 11387
Solubility (25°C) * In vitro DMSO 83 mg/mL (200 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.41446 4.1446 8.2892 12.4338

Research Area

Customer Reviews (1)


Click to enlarge
Rating
Source Blood, 2012, 120(19):4093-103. CYT387 purchased from Selleck
Method Flow cytometric analysis
Cell Lines WT pan T cells
Concentrations 1 uM
Incubation Time
Results CYT387 dramatically reduced the expression of CXCR3 in activated WT T cells.

Product Citations (1)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related JAK Inhibitors

  • Pacritinib (SB1518)

    Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM, respectively.

  • XL019

    XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.

    Features:High oral bioavailability in multiple species.

  • ZM 39923 HCl

    ZM 39923 is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.

    Features:ZM39923 acts as a prodrug.

  • Ruxolitinib (INCB018424)

    INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.

  • Tofacitinib (CP-690550) Citrate

    Tofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

  • AZD1480

    AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2.

  • TG101348 (SAR302503)

    TG-101348 (SAR302503) is a selective inhibitor of JAK2 with IC50 of 3 nM, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 1/2.

  • AT9283

    AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM; also potent to Aurora A/B, Abl(T315I). Phase 1/2.

  • CYT387

    CYT387 is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 1/2.

  • Tofacitinib (CP-690550,Tasocitinib)

    Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

Recently Viewed Items

Tags: buy CYT387 | CYT387 supplier | purchase CYT387 | CYT387 cost | CYT387 manufacturer | order CYT387 | CYT387 distributor
Contact Us